Research · Sep 3, 2026
EBS: FY25 Deep Dive
Emergent BioSolutions FY25 at $743M. NI $53M; EPS $0.93.
EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.20
−0.56%Research · Aug 25, 2026
Vaccine Procurement Shifts From Outbreak Awards to Standing Budgets
Bavarian Nordic, SIGA, Emergent and Valneva told August 2026 calls that sovereign and multilateral budgets, not outbreak awards, now drive vaccine orders.